NeVap Inc

NeVap Inc manufactures airway management devices focused on infection prevention and critical care outcomes. The company's flagship product is the Aspire Subglottic Endotracheal Tube (ASSET), a subglottic suction breathing tube engineered with a tissue spacer and multiple drainage ports to prevent tissue blockage during suctioning. The ASSET is designed to reduce ventilator-associated pneumonia (VAP), post-operative pneumonia, and aspiration pneumonia incidence by enabling effective subglottic drainage in ICU, operating room, and emergency department settings. Clinical evidence demonstrates that subglottic drainage reduces mechanical ventilation duration, pneumonia incidence, antibiotic consumption, and mortality in long-term ventilated patients. The device is supported by recommendations from the CDC, AHRQ, ATS, SHEA, APIC, IDSA, and AACN. NeVap's leadership includes medical device executives and FDA compliance experts, with an advisory board composed of life sciences professionals. The company is positioned to serve hospitals and healthcare systems across the Bay Area and beyond, addressing a significant clinical need in airway management and infection prevention protocols.